Alexandria T M Lee
Overview
Explore the profile of Alexandria T M Lee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
20
Followers
0
Related Specialties
Related Specialties
Co-Authors
Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arter Z, Lee A, Nagasaka M, Ou S
Cancer Med
. 2025 Feb;
14(4):e70665.
PMID: 39950716
Background: Receptor tyrosine kinase (RTK) inhibitors have been approved for the treatment of NTRK fusion (NTRK+) and RET fusion (RET+) positive solid tumors in a tumor-agnostic manner. However, the objective...
2.
3.
Lee A, Nagasaka M
Lung Cancer (Auckl)
. 2024 Dec;
15:169-176.
PMID: 39717628
Mutations in KRAS G12C are among the more common oncogenic driver mutations in non-small cell lung cancer (NSCLC). In December 2022, the US Food and Drug Administration (FDA) granted accelerated...
4.
Lee A, Ou S
Lung Cancer (Auckl)
. 2024 May;
15():75-80.
PMID: 38807655
Selpercatinib, a potent and highly selective RET kinase inhibitor with significant CNS activity, has recently gained US approval for the treatment of NSCLC harboring fusions (+) based on a large-scale...
5.
6.
Chen L, Lee A, Nagasaka M, Ou S
J Thorac Oncol
. 2024 Mar;
19(3):380-384.
PMID: 38453326
No abstract available.
7.
Lee A, Ou S
Lung Cancer (Auckl)
. 2024 Mar;
15:19-27.
PMID: 38433979
Despite the development and approval of seven anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) spanning over three "generations" since the discovery of fusion positive () non-small cell lung cancer...
8.
Lee A, Ou S
Med
. 2024 Feb;
5(2):115-117.
PMID: 38340706
Passaro et al. demonstrated in EGFR+ NSCLC post-1L osimertinib both "quad" (lazertinib [L] + amivantamab [A] + chemotherapy [CP]) and "triplet" (ACP) regimens achieved improved median progression-free survival over CP....
9.
Lee A, Ou S, Lisberg A
J Thorac Oncol
. 2023 Aug;
18(9):e97-e99.
PMID: 37599056
No abstract available.
10.
Lee A, Ou S
Lung Cancer (Auckl)
. 2023 Jul;
14:71-78.
PMID: 37440867
Alectinib, a next-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), has demonstrated superior progression-free survival over crizotinib with both 300 mg twice daily (J-ALEX) or 600 mg twice daily...